Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 74,000 shares of its common stock and granted an aggregate of 48,850 restricted stock unit ('RSU') awards to 20 new non-executive employees, in each case, under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the '2021 Inducement Plan'). The stock options and RSUs were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2021 Inducement Plan is used exclusively for granting equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $33.08 per share, which is equal to the closing price of Crinetics' common stock on the Nasdaq Global Select Market on June 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee's continued employment with Crinetics on such vesting dates. The RSUs will vest over four years in equal annual installments beginning on the one-year anniversary of the applicable vesting commencement date, also subject to each employee's continued employment with Crinetics on such vesting dates. The stock option and RSU awards are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of an applicable stock option award agreement or RSU award agreement covering the respective grant.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics' lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome. All of the company's drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
4 hours ago
- CTV News
CTV National News: Could a trade and security deal with the U.S. happen before the G7?
Watch Vassy Kapelos says steel and aluminum tariffs are what is presently holding up a possible economic and security agreement between Canada and the U.S.
Globe and Mail
5 hours ago
- Globe and Mail
World of EUC: Extraordinary Keynote in End User Computing
The World of EUC has announced an unprecedented keynote for its EUC World Amplify conference, set for August 4-7, 2025, in Minneapolis. Top technical experts from end user computing giants will take the stage for an unfiltered discussion of all things EUC. Charleston, South Carolina--(Newsfile Corp. - June 11, 2025) - The World of EUC (WEUC) has announced an unprecedented keynote panel for its second annual EUC World Amplify conference, scheduled for August 4-7, 2025, in Minneapolis, Minnesota. For the first time, top technical experts from end user computing (EUC) giants will take the stage together for an independent and unfiltered discussion of all things EUC. Extraordinary Keynote in End User Computing To view an enhanced version of this graphic, please visit: Confirmed panelists include: Andrew Morgan from AWS, Shawn Bass from Citrix, Ryan Costello from Google Cloud, Joe Rizkallah from Nutanix, Lokesh Batra from NVIDIA, Christopher Reed from Omnissa, and Christian Aquilina from Parallels. Titled "EUC Tomorrow, Today," the discussion will be moderated by WEUC Director Stephen Wagner. Registration is open at "This will be a real discussion providing real insight with an engaged, in-person community," said Wagner. "These panelists and their companies will shape this industry for the next decade and beyond. This is a huge learning opportunity for every EUC professional out there." The keynote is a live and in-person event. WEUC will not video record or share a transcript. Registration is open at Janna White, WEUC Director, said "Our board has 100 plus years of experience in the industry and we've never seen a panel with so much influence across EUC technologies. We are incredibly proud and grateful to the participants." "It is because of WEUC's independence and the participants' support for a strong EUC community that this is possible," said Jarian Gibson, WEUC Chairperson. "These panelists are smart. You can count on great insights. Let's Go!" WEUC is a nonprofit founded in 2024 to cultivate a thriving community where EUC professionals share insights, foster collaboration, and build connections. WEUC is an independent, inclusive and vendor-agnostic platform. Learn more here: EUC World Amplify is WEUC's 2025 in-person event drawing EUC professionals, vendors and channel partners from around the world. Learn more here: To view the source version of this press release, please visit
Winnipeg Free Press
6 hours ago
- Winnipeg Free Press
Asian shares are mixed as markets shrug at latest China-US trade deal
TOKYO (AP) — Asian shares were trading mixed early Thursday after Wall Street's rally stalled as investors appeared not to react much to the results of the latest round of China-U.S. trade talks. U.S. futures slipped while oil prices rose. Japan's Nikkei 225 lost 0.7% to 38,160.80. Hong Kong's Hang Seng sank 0.7% to 24,206.69, while the Shanghai Composite index edged 0.1% lower to 3,400.30. In South Korea, the Kospi gained 0.4% to 2,919.67, while Australia's S&P/ASX 200 edged 0.1% higher to 8,604.70. On Wednesday, the S&P 500 fell 0.3% to 6,022.24 for its first loss in four days. The Dow Jones Industrial Average was virtually unchanged at 42,865.77 after edging down by 1 point. The Nasdaq composite slipped 0.5% to 3,400.30. All told, the S&P 500 fell 16.57 points to 6,022.24. The Dow Jones Industrial Average slipped 1.10 to 42,865.77, and the Nasdaq composite sank 99.11 to 19,615.88. Several Big Tech stocks led the way lower, and a 1.9% drop for Apple was the heaviest weight on the market. It's been listless this week after unveiling several modest upcoming changes to the software that runs its devices. The action was stronger in the bond market, where Treasury yields eased after a report suggested President Donald Trump's tariffs are not pushing inflation much higher, at least not yet. U.S. consumers had to pay prices for food, gasoline and other costs of living that were 2.4% higher overall in May than a year earlier. That was up from April's 2.3% inflation rate, but it wasn't as bad as the 2.5% that Wall Street was expecting. A fear has been that Trump's wide-ranging tariffs could ignite an acceleration in inflation, just when it had seemed to get nearly all the way back to the Federal Reserve's 2% target from more than 9% three summers ago. It hasn't happened, though economists warn it may take months more to feel the full effect of Trump's tariffs. Trump said Wednesday that China will supply rare-earth minerals and magnets to the United States, while his government will allow Chinese students into U.S. universities in a deal that still needs an agreement by him and by China's leader. Trump also said that 'President XI and I are going to work closely together to open up China to American Trade. This would be a great WIN for both countries!!!' Investors are still hoping for a more sweeping trade deal that would ease tensions between the world's two largest economies. Hopes for such deals between the United States and countries around the world have been one of the main reasons the S&P 500 has charged nearly all the way back to its all-time high after dropping roughly 20% below a couple months ago. Without them, the fear is that Trump's high tariffs could drive the economy into a recession while pushing inflation higher. The S&P 500 is now sitting 2% below its record. Tesla swung between gains and losses before finishing with a rise of 0.1% to continue its shaky run. It's been recovering much of its big losses taken last week after Elon Musk's relationship with Trump imploded, which in turn raised fears about a loss of business for the electric-vehicle company. Musk on Wednesday backed away from some of his earlier comments and said they went 'too far.' In the bond market, the yield on the 10-year Treasury eased to 4.41% from 4.47% late Tuesday. Shorter-term yields, which more closely track expectations for what the Fed will do with overnight interest rates, fell more. Monday Mornings The latest local business news and a lookahead to the coming week. Wednesday's better-than-expected reading on inflation raised expectations along Wall Street that the Fed could cut its main interest rate at least twice by the end of the year. In other dealings early Thursday, U.S. benchmark crude oil gained 13 cents to $68.28 per barrel. Brent crude, the international standard, picked up 10 cents to $69.87 per barrel. The U.S. dollar slipped to 144.05 Japanese yen from 144.60 yen. The euro rose to $1.1521 from $1.1487. ___ AP Business Writer Stan Choe contributed.
